SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328700. A total of 43 filers reported holding SUNESIS PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $543,000 | -42.8% | 2,061,684 | -10.0% | 0.00% | – |
| Q1 2020 | $950,000 | +141.7% | 2,290,180 | +96.9% | 0.00% | – |
| Q4 2019 | $393,000 | -29.4% | 1,163,142 | +50.3% | 0.00% | – |
| Q3 2019 | $557,000 | -2.1% | 774,067 | -1.1% | 0.00% | – |
| Q2 2019 | $569,000 | +113.9% | 783,059 | +257.3% | 0.00% | – |
| Q1 2019 | $266,000 | +269.4% | 219,135 | +27.2% | 0.00% | – |
| Q4 2018 | $72,000 | -79.3% | 172,283 | -0.6% | 0.00% | – |
| Q3 2018 | $347,000 | -3.3% | 173,398 | +2.3% | 0.00% | – |
| Q2 2018 | $359,000 | -12.0% | 169,434 | +13.2% | 0.00% | – |
| Q1 2018 | $408,000 | -15.4% | 149,636 | +14.6% | 0.00% | – |
| Q4 2017 | $482,000 | +107.8% | 130,573 | +9.5% | 0.00% | – |
| Q3 2017 | $232,000 | -29.3% | 119,222 | -1.9% | 0.00% | – |
| Q2 2017 | $328,000 | -3.2% | 121,474 | +47.2% | 0.00% | – |
| Q1 2017 | $339,000 | – | 82,534 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 7,600,000 | $9,234,000 | 7.03% |
| Samsara BioCapital, LLC | 3,750,000 | $4,556,000 | 3.58% |
| CAXTON CORP | 277,245 | $337,000 | 0.31% |
| BVF INC/IL | 2,287,860 | $2,780,000 | 0.31% |
| Eventide Asset Management | 5,965,455 | $7,248,000 | 0.25% |
| Telemetry Investments, L.L.C. | 197,564 | $240,000 | 0.12% |
| NEA Management Company, LLC | 1,298,274 | $1,584,000 | 0.08% |
| RP Management, LLC | 129,517 | $158,000 | 0.08% |
| Palo Alto Investors LP | 1,162,473 | $1,412,000 | 0.06% |
| Fosun International Ltd | 725,000 | $863,000 | 0.06% |